Cost-Effectiveness Analysis of Prostate Specific Antigen Screening Among Chinese Men
Abstract
In the main text and Table 4 of the baseline results, there were 3 numerical discrepancies related to the decimal points. The figures for the costs of the clinical diagnostic strategy, the population-based screening strategy, and the incremental cost need to be shifted one decimal place forward. The corrected amounts are 36,985,783.05 CNY for the clinical diagnostic strategy, 48,069,831.44 CNY for the population-based screening strategy, and 11,084,048.38 CNY for the incremental cost of the population-based screening strategy.
Authors